<DOC>
	<DOCNO>NCT01072318</DOCNO>
	<brief_summary>The purpose study assess Efficacy Safety Extended Adjuvant Treatment With Letrozole Postmenopausal Women With Hormone Receptor Positive Breast Cancer Who Complete 5 Years Toremifene</brief_summary>
	<brief_title>Extended Adjuvant Treatment With Letrozole Breast Cancer Who Complete 5 Years Toremifene</brief_title>
	<detailed_description>1 . Primary purpose To evaluate disease free survival rate ( DFS ) take 36 month Letrozole postmenopausal woman hormone receptor positive breast cancer complete 5 year Toremifene 2 . Secondary purpose - To evaluate follow take 36 month Letrozole postmenopausal woman hormone receptor positive breast cancer complete 5 year Toremifene . 1 . Disease Free Survival rate ( DFS ) -12 month , 24 month 2 . Distant disease free survival rate ( DDFS ) , Overall Survival ( OS ) - 12 month , 24 month , 36 month c. safety - Change lipid profile - Mortality morbidity due Cardiovascular disease - Incidence Fracture - Change Bone density - Common toxic effect</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Toremifene</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>1 . Patients undergone surgery breast cancer prove histologically invasive breast cancer . 2 . Removed breast cancer histologically cytologically 3 . No evidence breast cancer controlateral breast 4 . No evidence metastasis 5 . Postmenopausal Women With Hormone Receptor Positive Breast Cancer Who Complete 5 Years Toremifene 30 month 6 . Postmenopausal state define follow condition , least one , b 1 . Serum FSH ≥ 30 mIU/mL 2 . Amenorrhea ≥ 1 year 7 . Estrogen receptor ( + ) Progesterone receptor ( + ) 8 . No Evidence Recurrence 1 . Patient hormone receptor negative 2 . Patients malignancies 3 . Patients aromatase inhibitor chemotherapy 4 . Patients Other hormone therapy Hormonal replacement therapy 5 . Patients Hormone replacement therapy take Toremifene 6 . Estimated life expectancy &lt; 12 month 7 . WBC &lt; 3,000/mm3 Platelet count &lt; 100,000/mm3 8 . AST and/or ALT ≥2xUNL 9 . Alkaline phosphatase ≥2xUNL</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>extend adjuvant hormonal therapy</keyword>
	<keyword>letrozole</keyword>
	<keyword>Toremifene</keyword>
</DOC>